Seven Corners Initiates Coverage on Allergan (AGN) With A Sell, Due to Non-GAAP Accounting Concerns

January 20, 2017


Today Seven Corners Capital Management initiated coverage on Allergan (AGN). Specifically, we are short AGN for, among other things, the following reasons: (1) Last year the SEC issued guidance on impermissible non-GAAP financial metrics; (2) Allergan's "non-GAAP EPS" measure appears to violate these rules; and (3) Allergan will likely need to cease using (or substantial alter) its "non-GAAP EPS" metric. Due to the belief that AGN's true "economic earnings" are well below its "non-GAAP EPS" numbers and guidance, we view AGN as substantially overvalued currently.


To find a PDF containing our full AGN writeup, please visit our Research section (link here).

Please reload

Featured Posts

Seachange International (SEAC) - Q3 2019 Earnings Report

December 17, 2019

Please reload

Recent Posts
Please reload

Please reload

50 Vanderbilt Ave, 4th Fl, New York, New York 10017

Content © 2016 Seven Corners Capital Management, LLC. All rights reserved.

  • LinkedIn Social Icon
  • RSS Social Icon
  • Twitter Social Icon
  • SA
  • Image by sporlab